Trial Profile
Savolitinib Combine With Durvalumab in Chinese EGFR Wild-type Locally Advanced or Metastatic NSCLC Patients With MET Alteration: An Open-label, Interventional, Multiple-center, Exploratory Trial (SOUND)
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Savolitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SOUND
- Sponsors AstraZeneca
- 16 Jan 2024 Planned End Date changed from 31 Oct 2024 to 31 Dec 2024.
- 08 Aug 2023 Planned End Date changed from 31 May 2024 to 31 Oct 2024.
- 08 Aug 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2024.